INTRODUCTION
HbF (α2 γ2), the main haemoglobin component in the foetus, is present at levels of 65 to 90% at birth and usually drops to less than 2% by 6 to 12 months of age (1) . HbF levels may also be elevated as a result of genetic abnormalities of haemoglobin production or because of haemopoietic stress.
After birth, the HbF-gama-gene is switched down and the HbA beta-gene is switched on so that adults mainly produce HbA (α2 β2). After this developmental switch, low levels of HbF are still produced, and this is distributed heterogeneously with some red cells (F cells) expressing more HbF than others (2) . The level of HbF, and the associated proportion of F cells, is a highly heritable trait (3) , and within a normal population the distribution of HbF is much skewed. Most healthy individuals produce <0.6% HbF distributed among 1-7% F cells, but a small proportion (about 2%) produce up to 5% HbF and 25% F cells and such individuals are said to have heterocellular hereditary persistence of fetal Hb (hHPFH) (4) . SCA patients with high HbF levels not only have less severe clinical course, but also have mild clinical complications because an increase in haemoglobin F inhibits polymerization of sickle haemoglobin.
The varying levels of foetal haemoglobin in erythrocytes account for a larger part of clinical heterogene- ity observed in patients with sickle cell anaemia (5) . It is also a major prognostic factor for several clinical com-plications. (6, 7, 8) The strong relationship existing between percentage HbF level and disease severity in SCA suggests that baseline measurement of percentage HbF is paramount in predicting important aspects of clinical course and in advocating usage of hydroxyurea, which is in low ebb in Nigeria, in order to achieve as much as 40% reduction in mortality long observed in SCA by Steinberge et al in 2003 (9) MATERIALS AND METHODS Subjects Ninety seven subjects were enrolled. This included 66 SCA patients in steady state attending Medical Out Patient clinic who were consecutively recruited into the study after an informed consent. Also, 31 consent-ing healthy, HbAA adults were enrolled into the study. These were medical health workers or voluntary blood donors.
Sample Collection
Five milliliters of venous blood was collected by clean venepuncture from each patient via the antecubital vein using a plastic syringe with minimum stasis, into commercially prepared concentrations of sequestrene ethylene di-amine tetra-acetic acid (EDTA) bottles. Each sample was mixed gently and thoroughly to en-sure anticoagulation and to prevent cell lysis. One mil-liliter of this blood was used to prepare haemolysate for HbF estimation and haemoglobin electrophoresis using Cellulose acetate at pH 8.6 to confirm HbA and HbS status. Methodology Measurement of HbF was done using the Betke method (10) . HbF percentage was calculated using the formula: % HbF = A413 filtrate x100 A413 standard x 20 Statistical Analysis Statistical analysis was performed using SPSS 15.0. Results were expressed as mean ± SD. The difference between mean was compared using the Student's t test.
RESULTS
Ninety seven subjects made up of 66 diagnosed SCA (HbS) and 31 normal HbA controls were recruited. In the 66 SCA patients, 28 were males while 38 were females with a mean age of 27.9±10.4 (age range 15 to 60 years). The control subjects have a mean age of 30.6±8.1 years. There was no statistically significant difference in age of the controls and the patients (p = 0.314).
The mean HbF level for the control was 1.04±0.44 (range 0.2-1.7) while the mean for the SCA patients was 5.16±4.04. The difference in the mean HbF when compared was statistically significant (p = 0.000). In the SCA patients; the mean for males of 4.71 was slightly lower than the mean for females 4.99 although not statistically significant. (p = 0.773).
While the mean HbF in the controls fall within normal range of <1.5%; 45(68.2%) of the SCA patients has a raised HbF of within the range of 2.1%-10% and 7(10.6%) had HbF >10%. (Table2). Table 1 highlighting a steady decline in the mean HbF levels as age advances.
DISCUSSION
Foetal haemoglobin, a heritable traits in adults accounting for substantial phenotypic diversity of sickle cell disease; was estimated in both control subjects (HbAA and known HbSS patients in steady state for comparison. The mean haemoglobin F (HbF) level expected in HbAA controls is supposed to be <1.5% ) . Although, the mean of HbF in females of 4.99 was slightly higher than that of males (4.71), there was no statistically significant difference (p = 0.773). This finding may not agree with com-parative survival curve analysis study which found that male HbSS patients had a better overall prognosis than females (15) .Another local study found a statistically higher level of HbF in males than females.
(13)
Sickle cell anaemia (SCA) was the first human monogenic disorder to be characterized at the molecular level Although all patients with SCA have exactly the same molecular defect, there is considerable clinical variation, ranging from death in early childhood (18) , to a normal life span with few complications (4) due to the influence of genetic modifiers of SCA like co-exist-ence of á -thalassemia (19) . Therefore, patients with increased levels of HbF often tend to have a relatively mild clinical course (20) because HbF reduces the ten-dency of HbS to polymerize within the red cell. This highlights the need to determine HbF along with HbA 2 in assisting to differentiate HbSS, HbS-beta-thalassemia and HbS -HPFH and hence determination of HbA 2 and HbF should graduate from research activ-ity to routine tool in order to project the management of SCA to a level where the clinical course among others could be easily predicted at diagnosis.
Genetic studies have established that increased HbF level may result from rare deletions within the betaglobin gene cluster or from point mutations in the promoters of the fetal gamma-globin genes (heredi-tary persistence of fetal haemoglobin, HPFH), how-ever, additional loci are known to increase HbF levels in adult life, which has been identified using combina-tion of genome-wide analysis within a large kindred (21) and within twin pairs (22) , leading to identification of two quantitative trait loci (QTL) with major influences on fetal hemoglobin levels in adults. Lettre et al (23) had shown that a significant proportion of the variation in HbF levels and the frequency of painful crises in patients with SCA, are accounted for by five common single-nucleotide polymorphisms (SNPs) at these loci. A pharmacologic agent, Hydroxyurea, ( produced and in use since 1994), and its effectiveness was affirmed when a large multicenter, randomized,double blind placebo study in America of 299 subjects showed that the drug significantly reduced not only the frequency and severity of painful crises , but also the incidence of acute chest syndrome, and blood transfusionrequirements (24) . Its precise mechanism of action is unknown but itcauses an increase in fetal haemoglobin concentrations in mostsubjects by physically interfering with the polymerizationprocess of deoxyhaemoglobin S. Although hydroxyurea is not a cure for sickle cell disease but it should, at present, be offered to our severely affected SCA patients since the risk of severely symptomatic disease and early death is correlatedwith the fetal haemoglobin concentration (25) . The drug will be beneficial to 21% of SCA patients in this study whose %HbF levels fell below 2% and some of the 68.2% with %HbF ranging between 2.1%-10.0%.
It is highly imperative to always estimate not only the levels of HbF, but also of HbA2 so as to be able to clearly define the clinical course of every sickle cell disease patient. Resource poor countries should be assisted to equip their haemoglobinopathy laboratories to be able to have and use freely, equipments like Isoeletric focusing, High Performance Liquid Chromatographic (HPLC) studies and radial immunodiffusion, that will distinctly separate and quantify all hae-moglobin variants.
